# A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

> **NCT00862524** · PHASE1,PHASE2 · COMPLETED · sponsor: **Array BioPharma** · enrollment: 20 (actual)

## Conditions studied

- Advanced Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** ARRY-334543, EGFR/ErbB2 inhibitor; oral
- **DRUG:** Gemcitabine, nucleoside analogue; intravenous

## Key facts

- **NCT ID:** NCT00862524
- **Lead sponsor:** Array BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862524, "A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00862524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*